V

    vTv Therapeutics Inc (VTVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.00
    -0.36 (-1.11%)

    Market Cap: $127.95M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(23/38)
    Avg Surprise
    -128.91%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.16
    Range$-1.29 - $-1.06
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.88+24.1%
    60d ago$-1.04+10.2%
    30d ago$-1.04+10.2%
    7d ago$-1.04+10.2%
    Current$-1.16
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.47
    Range$-2.26 - $0.63
    3 analysts
    Revenue Consensus
    $16M
    Range$-10180000 - $27M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$-1.16---
    Jun 26
    		$-1.05$-0.75-40.00%Miss-14.1%
    Mar 26
    		$1.65$0.21+685.71%Beat+314.3%
    Dec 25
    		$-0.58$-1.09+46.69%Beat-5.1%
    Sep 25
    		$-1.08$-0.98-10.20%Miss-22.7%
    Jun 25
    		$-0.92$-0.82-12.20%Miss-13.7%
    Mar 25
    		$-0.77$-0.73-5.48%Miss+34.5%
    Dec 24
    		$-0.55$-0.87+36.55%Beat+66.9%
    Sep 24
    		$-0.88N/A+75.56%Beat+72.5%
    Jun 24
    		$-0.81N/AN/ABeat-1055.6%
    Mar 24
    		$-1.17N/AN/ABeat-1857.8%
    Dec 23
    		$-1.67$-0.07-2285.71%Miss+30.4%
    Sep 23
    		$-3.20$-0.08-3900.00%Miss-60.0%
    Jun 23
    		$-0.07$-0.07+0.00%Beat+95.6%
    Mar 23
    		$-0.06$-0.09+33.33%Beat+98.5%
    Dec 22
    		$-2.40$-2.40+0.00%Beat-2081.8%
    Sep 22
    		$-2.00$-1.80-11.11%Miss-150.0%
    Jun 22
    		$-1.60N/A+60.00%Beat-300.0%
    Mar 22
    		$-4.00$-3.20-25.00%Miss-25.0%
    Dec 21
    		$-0.11$-0.07-57.14%Miss-650.0%
    Sep 21
    		$-0.80N/A+71.43%Beat+33.3%
    Jun 21
    		$-0.40N/A+85.71%Beat+85.7%
    Mar 21
    		$-3.20$-2.40-33.33%Miss+27.3%
    Dec 20
    		$0.02N/A+140.00%Beat+115.4%
    Sep 20
    		$-1.20N/A+71.43%Beat+83.8%
    Jun 20
    		$-2.80$-3.80+26.32%Beat+22.2%
    Mar 20
    		$-4.40$-4.00-10.00%Miss-4788.9%
    Dec 19
    		$-0.13$-0.09-44.44%Miss+93.5%
    Sep 19
    		$-7.42$-6.40-15.94%Miss-209.2%
    Jun 19
    		$-3.60$-6.40+43.75%Beat+71.0%
    Mar 19
    		$-0.09N/A+62.50%Beat+99.3%
    Dec 18
    		$-2.00N/A+54.55%Beat+88.6%
    Sep 18
    		$-2.40$-4.80+50.00%Beat+84.2%
    Jun 18
    		$-12.40$-16.00+22.50%Beat+24.4%
    Mar 18
    		$-12.00$-16.40+26.83%Beat+31.8%
    Dec 17
    		$-17.60$-16.60-6.02%Miss-4090.5%
    Sep 17
    		$-15.20$-15.80+3.80%Beat+7.3%
    Jun 17
    		$-16.40$-18.00+8.89%Beat-
    Mar 17
    		$-17.60$-17.60+0.00%Beat-
    Dec 16
    		$-0.42$-0.28-50.00%Miss-
    Sep 16
    		$-16.40$-16.80+2.38%Beat-

    Key Metrics

    Valuation
    P/E Ratio-30.19EV/EBITDA-2.11x
    Price/FCF-23.69xFCF Yield-4.22%
    Profitability
    Profit Margin-12.90%Operating Margin-25.10%
    ROE-15.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio12.48xQuick Ratio12.48x
    Trading Statistics
    Beta0.29Avg Volume81.55K
    52-Week High$44.0052-Week Low$17.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$32.92
    SMA 20$32.85
    SMA 50$33.20
    SMA 200$34.33
    EMA 10$32.73
    EMA 20$32.73
    EMA 50$33.01
    EMA 200$31.99

    MACD

    Line: -0.03Signal: -0.03Hist: 0.00

    ADX

    ADX: 11.8+DI: 16.6-DI: 21.0

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down56.0
    PSAR$29.66

    Bollinger Bands

    Upper Band$35.58
    Lower Band$30.13
    %B Position1660%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    45.4

    Momentum Oscillators

    Stoch %K50.8
    Stoch %D54.8
    Williams %R-46.0
    ROC (10d)2.2%
    Momentum0.69
    CCI (20d)-59.4
    MFI (14d)36.6

    Volatility Measures

    ATR (14d)$1.73(5.4%)
    StdDev (20d)1.36
    Hist Vol46.1%(High)

    Volume Flow

    VWAP$31.86
    OBV330.3K
    AD Line-229.4K
    CMF (20d)-0.041

    Volume Metrics

    Avg Vol (20d)77.1K
    Vol Ratio1.2x
    VWMA (20d)$33.16

    Pivot Points

    R3$34.06
    R2$33.49
    R1$32.93
    Pivot Point$32.36
    S1$31.80
    S2$31.23
    S3$30.67

    Advanced Oscillators

    TSI-0.50
    Ultimate Osc46.9
    KST-4.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$36.84M$-24,000$0$0$0$17,000$0$0$1.00M$-9,000$0
    Cost of Revenue$0$0$2,000$0$0$0$22,000$0$0$0$23,000$0
    Gross Profit$0$36.84M$-2,000$0$0$0$17,000$0$0$1.00M$-23,000$0
    Operating Expenses$13.93M$13.58M$7.88M$10.70M$7.72M$6.50M$4.91M$6.51M$7.16M$6.63M$4.71M$5.37M
    R&D$8.77M$8.98M$3.91M$7.02M$4.10M$2.83M$2.23M$3.22M$3.44M$2.65M$2.14M$2.82M
    SG&A$5.16M$4.60M$3.98M$3.68M$3.62M$3.67M$2.67M$3.28M$3.72M$3.98M$2.57M$2.54M
    Operating Income$-13,930,000$23.26M$-7,885,000$-10,699,000$-7,721,000$-6,503,000$-4,892,000$-6,506,000$-7,155,000$-5,627,000$-4,707,000$-5,368,000
    Interest Income$812,000$838,000$865,000$399,000$275,000$331,000$429,000$504,000$553,000$79,000$88,000$131,000
    Interest Expense$0$0$1,000$5,000$0$0$0$0$0$292,000$0$4,000
    Income Before Tax$-13,054,000$24.13M$-7,138,000$-10,345,000$-7,380,000$-6,217,000$-4,437,000$-5,840,000$-6,409,000$-5,919,000$-4,441,000$-8,540,000
    Income Tax Expense$0$0$-2,459,000$0$0$0$0$0$0$100,000$0$0
    Net Income$-13,054,000$24.13M$-7,138,000$-10,345,000$-7,380,000$-6,217,000$-4,437,000$-5,840,000$-6,409,000$-6,019,000$-4,441,000$-8,540,000
    EBITDA$-13,865,000$23.30M$-7,135,000$-10,737,000$-7,652,000$-6,539,000$-4,844,000$-6,322,000$-6,939,000$-5,976,000$-4,499,000$-8,645,000
    EBIT$-13,866,000$23.30M$-7,137,000$-10,739,000$-7,655,000$-6,548,000$-4,866,000$-6,344,000$-6,962,000$-5,998,000$-4,522,000$-8,667,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VTVT

    News

    ETFs Investing in vTv Therapeutics, Inc. Class A Stocks

    This article lists ETFs that invest in vTv Therapeutics, Inc. Class A stocks, sorted by market value. It highlights two specific ETFs: iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS), providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and performance metrics for each. The piece aims to offer investors insights into opportunities to invest in vTv Therapeutics stocks through diversified funds.

    TradingView•8/23/26•
    Neutral

    vTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue

    vTv Therapeutics (VTVT) stock rose 2.2% despite reporting widening losses and zero revenue in Q2 2026. The company's net loss roughly doubled year-on-year to US$13.054m, and basic EPS swung to a loss of US$1.05. Investors appear to be focusing on the company's clinical pipeline, particularly a Phase III program in type 1 diabetes, rather than its current financial performance.

    Sahm•8/9/26•
    Somewhat-Bearish

    vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    vTv Therapeutics Inc. has reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin, a treatment for type 1 diabetes, in Q3 2026 and plans to initiate a Phase 2a hybrid closed-loop trial by the end of 2026. vTv Therapeutics also announced it has sufficient cash to fund operations through the anticipated CATT1 topline data readout and will host a Key Opinion Leader event in Q4 2026 to discuss cadisegliatin's potential.

    FinanzNachrichten.de•8/6/26•
    Bullish

    vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    vTv Therapeutics (Nasdaq: VTVT) announced its second-quarter 2026 financial results, highlighting that enrollment for its Phase 3 CATT1 trial for cadisegliatin, an oral therapy for type 1 diabetes, is expected to conclude in Q3 2026. The company plans to initiate a Phase 2a hybrid closed-loop trial (Hybrid CATT1) by the end of 2026 and expects its current cash reserves to fund operations through the anticipated CATT1 topline data readout. vTv Therapeutics also reported a net loss of $13.1 million for the quarter, compared to $6.0 million in the same period last year.

    GlobeNewswire•8/6/26•
    Bullish

    vTv expects type 1 diabetes trial enrollment to finish in Q3 2026

    vTv Therapeutics announced its Q2 2026 financial results, reporting a net loss of $13.1 million but maintaining sufficient cash to fund operations through the anticipated topline data readout of its Phase 3 CATT1 trial. Enrollment for the CATT1 trial, which evaluates cadisegliatin for type 1 diabetes, is expected to complete in Q3 2026, with a Phase 2a Hybrid CATT1 study commencing before the end of 2026. The company also plans to host a Key Opinion Leader event in Q4 2026 to discuss cadisegliatin's potential for T1D.

    Stock Titan•8/6/26•
    Neutral

    Frequently Asked Questions About VTVT

    Does VTVT pay dividends?
    vTv Therapeutics Inc (VTVT) does not currently pay a regular dividend.
    What is VTVT's market cap?
    vTv Therapeutics Inc (VTVT) has a market capitalization of $127.95M with a current stock price of $32.00.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In